

Curriculum Vitae

PERSONAL DATA

Name: Sandeep Vijan
Citizenship: United States

EDUCATION

Sept. 1981- June 1985 Diploma, Athens High School, Troy, Michigan

Sept. 1985- May 1989 B.S., University of Michigan, Ann Arbor, Michigan

July 1988- May 1992 M.D., University of Michigan, Ann Arbor, Michigan

Sept. 1995- June 1997 M.S. in Clinical Research Design and Statistical Analysis
University of Michigan School of Public Health and Rackham
School of Graduate Studies, Ann Arbor, Michigan

POSTDOCTORAL TRAINING

June 1992- July 1995 Residency, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan

ACADEMIC APPOINTMENTS

July 1995- June 1997 AHCPR Health Services Research Fellow, Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, Michigan

July 1997- present Investigator, Veterans' Administration Health Services Research and Development, Ann Arbor, Michigan

July 1997- June 1999 Lecturer, Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, Michigan

Sept. 1999- Sept. 2006 Assistant Professor, Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, Michigan

Sept. 2006- Associate Professor, Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, Michigan

ACADEMIC ADMINISTRATIVE APPOINTMENTS

July 1998- June 2001	Associate Director, Michigan Diabetes Research and Training Center, Modeling Core
-------------------------	--

CLINICAL HOSPITAL APPOINTMENTS

July 1995- present	Staff Physician, Ann Arbor Veterans Administration Health System
-----------------------	---

July 1997- present	Staff Physician, University of Michigan Health System
-----------------------	---

CONSULTING POSITIONS

July 1998- management present	American College of Physicians, PIER module for the of type 2 diabetes
-------------------------------------	---

July 1999- present	American College of Physicians, treatment of cardiovascular risk factors in type 2 diabetes
-----------------------	--

November 2003- present	BMJ Clinical Evidence; Treatment of hypertension in type 2 diabetes
---------------------------	--

December 2004- present	American College of Physicians; Diabetes Care Improvement Initiative.
---------------------------	--

October 2005- present	Harvard University Center for Health Systems Improvement, Expanding the National Health Accounts
--------------------------	---

SCIENTIFIC AND RESEARCH ACTIVITIES

EDITORIAL BOARDS

Medical Care Research and Review

MANUSCRIPT REVIEW

Journal of General Internal Medicine
The Lancet
Annals of Internal Medicine
Journal of the American Medical Association
Archives of Internal Medicine

American Journal of Medicine
Medical Care
Diabetologia
Effective Clinical Practice
Diabetic Medicine
Diabetes Care
Gastroenterology
American Journal of Managed Care
Journal of the American College of Cardiology
American Journal of Gastroenterology
Pharmacoeconomics
Medical Decision Making
Translational Research

STUDY SECTIONS

Chair, Veterans Affairs Health Services Research & Development Scientific Review and Evaluation Board (Implementation and Management Research) (2004-present)

Veterans Affairs Quality Enhancement Research Initiative (2001-2003)

GRANT SUPPORT

Current

1. Consultant, "Quality Enhancement Research Initiative, Diabetes." Veterans Administration DIB 98-001, direct costs \$200,000 annually (renewable). Rodney A. Hayward, PI. 10% effort for each year (most recent funding renewal 10/1/2006-9/30/2007).
2. Principal investigator, "The cost-effectiveness of genetic screening for colon cancer". National Institutes of Health, National Cancer Institute. Grant 1 R01 CA106782-01. Direct costs \$450,000 over 3 years. 37% effort per year. Funded on first submission (percentile score = 9.5). Funding dates 6/5/2004-5/31/2007; no-cost extension through 5/31/2008.
3. Co-investigator, "Insulin Treatment Variation in Southwestern Diabetics: Therapeutic Decision-making." VA HSR&D IIR 04-176; 5% effort per year. PI: Martha Jane Mohler, Tucson VA. Funding dates May 1, 2005-April 30, 2008.
4. Co-investigator, "Telephone Peer Support for Insulin Management among VA Diabetes Patients". VA HSR&D IIR 04-239. 5% effort per year. Co-PI's John Piette and Michele Heisler. Funding dates April 1, 2006-March 30, 2010.
5. Site Principal Investigator, "The Effect of Patient Adherence on the Cost-Effectiveness of Screening for Colorectal Neoplasia." National Institutes of

Health, National Cancer Institute. Grant R01 CA106773. Direct costs \$1,100,000 over 3.5 years; 10% effort per year. Funding dates July 1, 2006 – December 31, 2009.

6. Principal Investigator, “Patient preferences and endoscopy demand in VHA”. VA HSR&D RRP 06-189. 15% effort; funding dates 10/1/2006-3/31/07.

Pending

1. Co-Investigator, “The Impact of Diabetes Control on Work Employment and Productivity.” 15% effort for 15 years. Direct costs \$1.73 million over 5 years. NCI R01 DK074717. Resubmission March 1, 2006.
2. Co-Principal Investigator, “The effect of tailored colorectal cancer screening recommendations on screening adherence”. 15% effort. VA IIR submission December 15, 2006. Score 21.6; funding decision pending (funding line below ~22). Direct costs \$900,000 over 3 years.
3. Principal Investigator, “Improving quality measurement using quality-adjusted life years”. 20% effort. VA IIR submission December 15, 2006. Score: 17 (funding line below ~22); anticipated funding date September 2007. Direct costs \$411,200 over 3 years.
4. Core investigator, Model Integration Core. “Expanding the National Health Accounts”. NIH P01, number assignment pending. Total project direct costs \$1.5 million per year; core funds \$140,000 in year 1. 5% effort per year. Submitted March 15, 2007.
5. Co-investigator, “The value of interventions for cardiovascular disease in the elderly”. 10% effort year 1, 13.75% years 2-3, 15% years 4-5. NIH R01, number assignment pending. Direct costs \$850,000 over 5 year. Submitted March 15, 2007.
6. Core investigator, Michigan Diabetes Research and Training Center, Biostatistics and Modeling Core. 5% effort over 5 years.

Completed

1. Principal Investigator, Mentored Career Development Award. “Diabetes Care: Optimizing Quality, Minimizing Risk. Veterans Administration. 100% salary support for 3 years (funding date 1/1/2001).
2. Principal Investigator, “Patient Preferences and the Care of Diabetes.” Veterans Administration HSR&D IIR 970781, direct costs \$284,380. 20% effort for 2.5 years (funding dates 9/1/98-3/1/01).

3. Associate Director, Modeling Core, Michigan Diabetes Research and Training Center. NIH (NIDDK) P60-DK20572. 5% effort for 5 years.
4. Principal Investigator, "The impact of chronic diseases on work-force participation". Social Security Administration/Michigan Retirement Research Center grant UM01-11, direct costs \$100,000. 10% effort for 1 year (funding date 10/1/2000, effort donated as of 1/1/01).
5. Co-Investigator, "Developing Electronic Communications-Based Interventions Between Patients and Providers to Improve Cancer Control in the Primary Care Setting." Michigan Department of Community Health, contract #20011001, direct costs \$138,500. 5% effort (donated) for one year (funding date 10/1/00).
6. Co-Investigator, "Proactive Diabetes Case Management." Veterans Administration HSR&D IIR 970771, direct costs \$749,940. 5% effort for 3.5 years (funding date 9/1/98).
7. Co-Investigator, "Proactive Identification of Patients At-Risk for High Utilization: *Using the MCDR Telephone Interview*." University of Michigan Faculty Group Practice Academic Venture Investment Fund VIF.FY99.065, direct costs \$178,917. 5% effort (donated) for 2 years (funding date 2/1/00).
8. Co-Investigator, "Evaluating a web-based tailored information and feedback program to improve colon cancer screening rates in the primary care setting: A randomized controlled trial" Michigan Department of Community Health, contract #20011001, direct costs \$240,000. Steven Katz, PI. 10% effort (donated) for 9 months (funding date 1/1/02; no cost-extension ongoing through 12/31/03).
9. Co-Investigator, "Implications of High Risk Health Behaviors on Work-Force Participation: Disability, Retirement, and Lost Productivity. Social Security Administration/Michigan Retirement Research Center grant 02-12, direct costs \$50,000. Caroline Richardson, PI. 10% effort for 1 year (funding date 1/1/2003).
10. Principal Investigator, "Modeling the health impacts of disparities in diabetes care". Commonwealth Fund; 20% effort; subcontract through David Nerentz, PhD, PI, Henry Ford Health System. Funding date 2/1/2004-7/30/2004.
11. Principal investigator, "Measuring the value of diabetes disease management." Agency for Healthcare Research and Quality. 15% effort; subcontract through Joe Selby, MD, MPH, Kaiser Permanente Northern California. Funding dates 1/1/2004-4/1/2005.
12. Co-Investigator, "An Evaluation of a Coordinated Proactive Diabetes Eye Care Program". Veterans Administration QUERI; direct costs \$499,595 over 2 years. 10% effort. Steven Bernstein, PI. Funding date 1/2/2004.

CERTIFICATION AND LICENSURE

Medical Licensure: State of Michigan (4301059382) (expires 1/31/09)
Federal DEA (BV4843808) (expires 5/31/08)

Board Certification: Certified in Internal Medicine, 2005-2015

MILITARY SERVICE

None

HONORS AND AWARDS

House Officer Research Award, Department of Internal Medicine, University of Michigan, 1994-1995

Outstanding Research Award, Midwest Society of General Internal Medicine, 1996

Top 10 abstract, University of Michigan Research Day, 1997

Outstanding Research Award, Midwest Society of General Internal Medicine, 1997

Chair, VA HSR&D Scientific Review and Evaluation Board, Implementation and Management Section, 2004-present

Elected to Central Society for Clinical Research, 2006

MEMBERSHIP IN PROFESSIONAL SOCIETIES

American Medical Student Association, 1989-1992

Member, American College of Physicians, 1994-present

Society of General Internal Medicine, 1996-present

TEACHING ACTIVITIES

House officer mentor, Veterans Administration Primary Care Clinic, Ann Arbor, Michigan, 1996-present (rated in top quintile of faculty by residents, 2002-2004, received teaching bonus in 2003, 2004).

Management of Type 2 Diabetes lecture, University of Michigan Primary Care Conference, 1996.

Discussion leader, health policy sequence, second year medical students
Topic: physician supply issues. 1996-present.

Discussion leader, health policy sequence, second year medical students
Topic: guideline development and dissemination. 1996-present.

Discussion leader, health policy sequence, second year medical students.
Topic: The changing role of physicians under managed care. 1998-9, 1999-2000.

Discussion leader, second year medical students, endocrinology sequence. Topic:
Evaluation of the medical literature, 1996-2002.

Discussion leader, "Critical Appraisal of the Medical Literature," fourth year
medical students, 1996-present. Topic: guideline evaluation.

Discussion leader, problem-based learning ethics sequence, Introduction to the
Patient, first year medical students, 1997-8

Lecturer, M2 Gastrointestinal sequence, "Colorectal cancer screening", 2000, 2004.

Attending physician, inpatient morning report, 1997-present..

Attending physician, intern report. 1999-present..

Attending physician, Chief of Medicine Rounds, 1998-present.

Attending rounds, inpatient medical service, Veterans Administration Medical
Center, 1997-present..

Attending physician, residents' journal club, 1998-99, 1999-2000

Ambulatory care conference on critical appraisal and interpretation of the medical
literature, 1997-8

Instructor, Robert Wood Johnson Clinical Scholars Summer Session, 1998-present

Noon conference, "Update in diabetes management", 1998, 2003, 2005, 2006.

Management of Diabetes Mellitus (Update). Co-author. Audience: primary care
clinicians and other health care providers who treat adults with this condition.
(Available through the UM CME web site: cme.med.umich.edu). 1998.

University of Michigan Grand Rounds, 2000. “Risk stratification in medicine: application of clinical predictors of risk to clinical decision-making”

Noon conference, “Screening for cancer in primary care”, 1999, 2001, 2003.

Evidence-based management of hypertension in type 2 diabetes. American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.

Evidence-based management of lipids in type 2 diabetes. American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.

Setting appropriate standards of care in type 2 diabetes. American College of Physicians. Philadelphia, PA, October 2003; October 2004.

Adult Preventive Health Care: Cancer Screening (update). Co-author. Audience: primary care clinicians and other health care providers who treat adults with this condition. (Available through the UM CME web site: cme.med.umich.edu). 2004.

Management of Type 2 Diabetes Mellitus (Update). Co-author. Audience: primary care clinicians and other health care providers who treat adults with this condition. (Available through the UM CME web site: cme.med.umich.edu). 2004.

MENTORING

Senior research project mentor, Erik-Jan Wamsteker, M.D., 1999. Cost-effectiveness of carotid endarterectomy in symptomatic patients with 50-69% stenoses

Senior research project mentor, Jim Lavelle, M.D., 2001-2. Predictors of positive blood cultures in patients admitted with community-acquired pneumonia.

Senior research project mentor, David Deguzman, M.D., 2002-3. Adherence and follow-up of fecal occult-blood testing for colorectal cancer screening.

Senior research project mentor, Gregory Bump, M.D., 2002-3. The impact of chronic diseases on self-management of type 2 diabetes.

Senior research project mentor, Ghazala Khan, M.D., 2003-4. Estimating the accuracy of echocardiography in predicting right ventricular systolic pressure.

Senior research project mentor, Sachin Parikh, M.D., 2004-2006. Cost-effectiveness of electrophysiologic studies to stratify ICD implantation.

Fellowship mentor, Peter Cram, MD, MBA, 2001-2003. Cost-effectiveness of external defibrillators; effects of celebrity spokespeople on health behaviors.

Fellowship mentor, Michele Heisler, MD, MPA. Patient and provider concordance on priorities in diabetes care.

Fellowship/junior faculty mentor, Allison Rosen, MD, ScD, 2003-2004. Should Medicare cover ACE inhibitors for patients with diabetes? A cost-utility analysis. *Winner of best paper, Society for Medical Decision Making, 2005-6.*

Fellowship mentor, Paul Chan, MD, 2004-2007. Effectiveness and costs of catheter ablation of atrial fibrillation; effectiveness of ICDs in clinical practice; cost-effectiveness of risk-stratifying ICD implantation. *Winner of ACC young investigator award for best presentation, ACC conference, 2006. Winner of award for best paper in Journal of the American College of Cardiology, 2006.*

Fellowship mentor, Sameer Saini, MD, 2004-2007. Effectiveness of surveillance colonoscopy for colorectal cancer; Colorectal cancer screening in women; Pay-for-performance and colorectal cancer screening.

Fellowship mentor, Michael Volk, MD, 2006-2007. Effectiveness of allocation strategies for liver transplantation.

Fellowship mentor, Cheerag Patel, MD, 2006-7. Cost-effectiveness of side airbag deployment in the US.

INVITED PRESENTATIONS

Cost-effectiveness of virtual colonoscopy for colorectal cancer screening. 7th International Virtual Colonoscopy Symposium. Boston, MA, October 16, 2006.

Moderator, Chronic Disease Management Abstract Session. SGIM Annual Meeting; Los Angeles, CA, April 2006.

Evidence-based management of hypertension in type 2 diabetes. American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.

Evidence-based management of lipids in type 2 diabetes. American Diabetes Association Annual Practice Update; Portland, OR, October 15, 2004.

Economic issues in diabetes-related vision impairment. Centers for Disease Control, Economics of vision impairment: public health prevention opportunities. Atlanta GA, June 4, 2004.

Moderator, quality of care abstract session. SGIM Annual Meeting; Chicago, IL, May 2004.

Moderator, diabetes abstract session. VA HSR&D Annual Meeting; Washington, DC, March 2004.

The cost-effectiveness of screening for colorectal cancer. National Academy of Sciences, Institute of Medicine. Conference on Economic Modeling in Colorectal Cancer. Washington, DC, January 25-27, 2004.

Setting appropriate standards of care in type 2 diabetes. American College of Physicians. Philadelphia, PA, October 2003, October 2004.

Screening for colorectal cancer: an updated view of the literature. Mackinac Island Internal Medicine Update, Mackinac Island, MI, August 2003.

Prevention of cardiovascular disease in type 2 diabetes. *Mackinac Island Internal Medicine Update, Mackinac Island, MI, August 2003.*

Emerging paradigms in medicine: risk-stratifying screening for diabetic retinopathy. Mackinac Island Internal Medicine Update, Mackinac Island, MI, August 2003.

The cost-effectiveness of prevention of cardiovascular disease in type 2 diabetes. Common Problems in Office Practice symposium, Dearborn, MI. April 2003.

The impact of diabetes on work-force participation: results from a national sample. Social Security Retirement Research Consortium Annual Conference, National Press Club, Washington DC, June 2002.

Cost-utility of screening for diabetic retinopathy. Evidence-Base for a Disease Management Programme for Type 2 Diabetes. Frankfurt, Germany, January 2001. Sponsor: AOK-Bundesverband under the auspices of the European Diabetes Association (EASD).

Rates, predictors, and costs of disability in patients with type 2 diabetes. Michigan Retirement Research Council Health and Retirement Study seminar, January 2001.

The Importance of Patient Preferences when making treatment decisions in older patients. The Challenge of Diabetes Care in Older Adults, University of Michigan, September 2001.

Quality standards and the politics of medicine: How well-meaning people can cause blindness and death. Robert Wood Johnson Clinical Scholars, University of Michigan, April 2000.

Should we screen annually for diabetic retinopathy? Ophthalmology Grand Rounds, University of Michigan, April 2000.

COMMITTEE AND ADMINISTRATIVE SERVICES

Veterans Administration Hospital:

Chair, VA Ann Arbor Healthcare System Care Management Committee, 2003-2005

University of Michigan Medical School:

Chair/Project team leader, University of Michigan type 2 diabetes guidelines development team, 1996-present

University of Michigan preventive care guidelines: Colorectal cancer screening, 1998-present

National/International

Board member, VA HSR&D Field Based Scientific Advisory Board for Implementation and Management Research, 2004-present.

Panel member, National Institutes of Health consensus development conference on the management of celiac disease, June 28-30, 2004.

Chair, VA HSR&D Scientific Review and Evaluation Board, Implementation and Management Research section, 2004-2008.

Author, ACP PIER module for the management of type 2 diabetes, American College of Physicians, 1998-present

American College of Physicians evidence review and guidelines for the management of hypertension in type 2 diabetes, 2001-present

American College of Physicians evidence review and guidelines for the management of lipids in type 2 diabetes, 2002-present

Author, British Medical Journal Clinical Evidence, Management of hypertension in type 2 diabetes.

American Academy of Family Physicians and American Diabetes Association guidelines for glycemic control in type 2 diabetes, 1998-9

Assessing the Care of Vulnerable Elders, Type 2 Diabetes, RAND quality indicator development, 1999

Abstract review committee, VA HSR&D Annual Meeting, 2000, 2001, 2002, 2003

Abstract review committee, National Association of Inpatient Physicians Annual Meeting, 2002

Abstract review committee, VA QUERI Annual Meeting, 2003

Abstract review committee, VA Office of Research and Development Annual Meeting, 2003, 2004

Abstract review committee, Society of General Internal Medicine National Meeting, 2002, 2003, 2004

Chair, chronic disease workshop sub-committee, Society of General Internal Medicine National Meeting, 2004-5

Chair, Chronic disease care and management scientific abstract committee, Society of General Internal Medicine National Meeting, 2005-6

Regional

Member, Greater Detroit Area Health Council Quality Forum Clinical Work Group, Diabetes sub-group, 1997-8.

Member, Daimler-Chrysler Evidence-Based Medicine in Action, diabetes practice guideline development committee, 1998.

RESEARCH EXPERIENCE

The Use of Inhaled Aminoglycosides in the Treatment of Nosocomial Pneumonia, Senior Research Project, April 1995

Oropharyngeal Bacterial Colonization in Nursing Home Patients, 1989

Research Fellow, Center for Practice Management and Outcomes Research, Ann Arbor Veterans Administration Medical Center, 1995-1997.

References available upon request.

BIBLIOGRAPHY

Peer-reviewed publications

1. Vijan S, Stevens DL, Funnell MM, Greene DA, Harrison RV, Herman WH, Hiss RG, Martin CL, Piehl EJ, Ratliff BJ, Standiford CJ. Management of Type II Diabetes Mellitus. Ann Arbor, MI: Office of Clinical Affairs, University of Michigan Health System, 1996. [practice guideline]
2. Vijan S, Steven D, Herman WH, Funnell M, Standiford C. *Prevention, Treatment, and Counseling for the Prevention of Complications in Type II Diabetes. Putting Evidence into Practice*. Journal of General Internal Medicine. 1997; 12(9): 567-580.[abstracted in ACP Journal Club 1998; 128(2).]
3. Vijan S, Hofer TP, Hayward RA. *Estimated Benefits of Glycemic Control in Type 2 Diabetes*. Annals of Internal Medicine. 1997; 127(9): 788-795. [abstracted in Journal Watch 1997; 17 (23): 186-7]; [abstracted in American Journal of Managed Care 1998; 4(4): 480].
4. Goold SD, Vijan S. *Normative Issues in Cost Effectiveness Analysis*. Journal of Laboratory and Clinical Medicine. 1998; 132(5): 376-382.
5. Vijan S, Stevens DL, Funnell MM, Greene DA, Harrison RV, Herman WH, Hiss RG, Martin CL, Piehl EJ, Ratliff BJ, Standiford CJ. Management of Diabetes Mellitus (Update). Ann Arbor, MI: Office of Clinical Affairs, University of Michigan Health System, 1998. [Was available from the Agency for Healthcare Research and Quality at www.guideline.gov] [practice guideline]
6. Vijan S, Kent DM, Hayward RA. *Are randomized controlled trials sufficient evidence to guide clinical practice in type 2 diabetes mellitus?* Diabetologia. 2000;43: 125-30.
7. Vijan S, Hofer TP, Hayward RA. *A cost-utility analysis of screening intervals for diabetic retinopathy*. JAMA. 2000; 283(7): 889-896. [abstracted in the Detroit News; Reuters health; CBShealthwatch.com; Healthscout.com; WebMD.com]
8. Hofer TP, Vijan S, Hayward RA. *Effectiveness of screening for type 2 diabetes on prevention of microvascular complications*. International Journal of Technology Assessment in Health Care; 2000; 16(3):822-833
9. Vijan S. *Are we overvaluing performance measures?* Effective Clinical Practice. 2000;3(5): 247-249.

10. Valenstein M, Zeber J, Boehm K, Buttar A, Vijan S. *Should we screen for depression in primary care?. A cost-utility analysis.* Annals of Internal Medicine. 2001; 134:345-60.
11. Shekelle PG, Vijan S. *Quality indicators for the management of diabetes mellitus in vulnerable elders.* Annals of Internal Medicine. 2001; 135(8, part 2). Available at <http://www.acponline.org/sci-policy/acove/>
12. Kerr EA, Krein SL, Vijan S, Hayward RA. *Avoiding pitfalls in chronic disease quality measurement: A case for the next generation of technical quality measure.* American Journal of Managed Care. 2001; 7(11): 1033-1043.
13. Vijan S, Hwang E, Hofer TP, Hayward RA. *Which colon cancer screening test? A comparison of costs, effectiveness, and compliance.* American Journal of Medicine. 2001; 111: 593-601.
14. Nallamothu BK, Saint S, Ramsey S, Hofer TP, Vijan S, Eagle KA. *The role of hospital volume in coronary artery bypass grafting: Is more always better?* Journal of the American College of Cardiology. 2001; 38: 1923-30.
15. Langa KM, Vijan S, Blaum C, Kabeto MU, Chernew ME, Hayward RA, Katz SJ, Willis RJ, Fendrick AM. *The quantity and cost of informal caregiving for the elderly with diabetes: estimates from a nationally representative sample.* Journal of Gerontology. 2002; 57B: S177-S186.
16. Krein SL, Vijan S, Pogach LM, Hogan MM, Kerr EA. *Aspirin use and counseling about aspirin among patients with diabetes in VA.* Diabetes Care. 2002; 25: 965-970.
17. Kent DM, Griffith JL, Hayward RA, Vijan S, Beshansky J, Califf RM, Selker HP. *An independently-derived model for selecting patients likely to benefit from tissue plasminogen activator: Validating with GUSTO.* American Journal of Medicine. 2002; 113:104-111.
18. Vijan S, Hayward RA. *Treatment of hypertension in type 2 diabetes: Blood pressure goals, choice of agents, and setting priorities in diabetes care.* Annals of Internal Medicine. 2003; 138: 593-602. [abstracted by WebMD.com]
19. Cram P, Vijan S, Wolbrink A, Fendrick AM. *The impact of including passive benefits in cost-effectiveness analysis: The case of automated external defibrillators on commercial aircraft.* Value in Health. 2003; 6(4): 466-73.
20. Cram P, Inadomi J, Cowen ME, Carpenter D, Fendrick AM, Vijan S. *The impact of a healthy celebrity spokesperson on preventive health behavior: the Katie Couric effect.* Archives of Internal Medicine. 2003; 163(13): 1601-5.

21. Cram P, Vijan S, Fendrick AM. *Cost-effectiveness of automated external defibrillation deployment in selected public locations*. Journal of General Internal Medicine. 2003;18(9): 745-54.
22. Heisler M, Vijan S, Anderson RM, Ubel PA, Bernstein SJ, Hofer TP. *When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make?* Journal of General Internal Medicine. 2003; 18(11): 893-902.
23. Vijan S, Hayward RA. *Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus*. Annals of Internal Medicine. 2004; 140: 650-8. [abstracted in the New York Times; Web MD]
24. Langa KM, Valenstein MA, Fendrick AM, Kabeto MU, Vijan S. *Informal caregiving for older Americans with symptoms of depression*. American Journal of Psychiatry. 2004; 161: 857-863.
25. Krein SL, Klamerus ML, Vijan S, Lee J, Fitzgerald JT, Pawlow A, Reeves P, Hayward RA. *The effectiveness of proactive diabetes case management for high-risk patients*. American Journal of Medicine. 2004; 116(11):732-739.
26. Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky JR, Selker HP. *Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction*. Journal of Clinical Epidemiology. 2004; 57(8): 843-852.
27. Vijan S, Inadomi J, Hayward RA, Hofer TP, Fendrick AM. *Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the US*. Alimentary Pharmaceuticals and Therapeutics. 2004; 20: 507-515.
28. Vijan S, Hayward RA, Langa KM. *The impact of diabetes on work-force participation: results from a national household sample*. Health Services Research. 2004; 39(6): 1653-69.
29. Vijan S, Stevens DL, Funnell MM, Herman WH, Lash RW. Management of Type 2 Diabetes Mellitus (Update). Ann Arbor, MI: Office of Clinical Affairs, University of Michigan Health System, 2004. [Available from the Agency for Healthcare Research and Quality at www.guideline.gov] [practice guideline]
30. Bernstein SJ, Ruffin MT, Vijan S, Harrison RV, Standiford CJ. Adult Preventive Health Care: Cancer Screening (Update). Ann Arbor, MI: Office of Clinical Affairs, University of Michigan Health System, 2004. [Available from the Agency for Healthcare Research and Quality at www.guideline.gov] [practice guideline]

31. Vijan S, Stuart N, Fitzgerald JT, Ronis DL, Hayward RA, Slater SS, Hofer TP. *Barriers to following dietary recommendations in type 2 diabetes*. Diabetic Medicine. 2005; 22: 32-38.
32. Nallamotheu BK, Saint S, Hofer TP, Vijan S, Eagle KA, Bernstein SJ. *Hospital volume and outcome in coronary artery bypass grafting: A risk paradox?* Archives of Internal Medicine. 2005; 165: 333-337.
33. Heisler M, Piette JD, Spencer M, Kieffer E, Vijan S. *The relationship between knowledge of recent hemoglobin a1c values and diabetes care understanding and self-management*. Diabetes Care. 2005; 28(4): 816-822.
34. Choe H, Mitrovich S, Dubay D, Hayward RA, Krein S, Vijan S. *Proactive case management of high-risk patients with type 2 diabetes by a clinical pharmacist: a randomized controlled trial*. American Journal of Managed Care. 2005; 11: 253-60.
35. Rosen AB, Hamel MB, Weinstein MC, Vijan S. *Cost-effectiveness of Medicare coverage of angiotensin converting enzyme inhibitors for beneficiaries with diabetes*. Annals of Internal Medicine. 2005 July 19; 143: 89-99. [abstracted by WebMD, Associated Press, United Press International, the Los Angeles Times, Reuters Health, National Public Radio] Winner of best paper, Society for Medical Decision-Making, 2005-6.
36. Vijan S, Hayward RA, Ronis DL, Hofer TP. *The burden of diabetes therapy: implications for the design of effective treatment regimens*. Journal of General Internal Medicine. 2005; 20: 479-82.
37. Jones E, Vijan S, Fendrick AM, Deshpande S, Cram P. *Automated external defibrillator deployment in public schools and senior centers*. Prehospital Emergency Care. 2005 October; 9(4): 382-385.
38. Hayward RA, Kent DM, Vijan S, Hofer TP. *Reporting clinical trial results to inform clinical practice: The need to assess benefits and harms for lower versus higher risk patients*. Health Affairs; 2005 November/December; 24(6): 1571-1581.
39. Davis EN, Chung KC, Kotsis SV, Lau FH, Vijan S. *Cost-utility analysis of cast immobilization versus open reduction and internal fixation for acute non-displaced mid-waist scaphoid fractures*. Plastic and Reconstructive Surgery. 2006; 117: 1223-1235.
40. Hayward RA, Kent DM, Vijan S, Hofer TP. *Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis*. BMC Medical Research Methodology. 2006; 6: 18.

41. Cutler DM, Rosen AB, Vijan S. *Value of medical spending in the United States, 1960-2000*. New England Journal of Medicine. 2006; 355(9): 920-7. [Abstracted in The Wall Street Journal, the New York Times, Associated Press].
42. Hayward RA, Hofer TP, Vijan S. *There is no valid epidemiological evidence for or against titrating lipid therapy to proposed LDL goals. A solvable problem*. Annals of Internal Medicine. 2006; 145(7): 520-530. [Abstracted in the New York Times].
43. Chan P, Vijan S, Morady F, Oral H. *Cost-effectiveness of left atrial catheter ablation of atrial fibrillation*. Journal of the American College of Cardiology. 2006; 47(12): 2513-20.
44. Chan P, Fendrick AM, Bloomfield DM, Stein K, Bigger TJ, Vijan S. *Cost-effectiveness of ICD therapy and risk stratification with microvolt T-wave alternans testing in the MADIT-II population*. Journal of the American College of Cardiology. 2006; 48(1): 112-21.
45. Cram P, Katz D, Vijan S, Kent DM, Langa KM, Fendrick AM. *Implantable or external defibrillators for individuals at increased risk of sudden cardiac death: Where cost-effectiveness hits fiscal reality*. Value in Health. 2006; 9(5): 292-302.
46. Vijan S. *Should we abandon QALYs ready as a resource allocation tool?* Pharmacoeconomics. 2006; 234(10): 953-955.
47. Rein DB, Wirth K, Hoerger TJ, McCall N, Zhang P, Vijan S, Saadine J. *The economic burden of adult visual disorders in the United States*. Archives of Ophthalmology. 2006; 124:1754-1760.
48. Rosen AB, Cutler DM, Vijan S. *Trends in the value of coronary heart disease care in the US. 1987-2002*. Health Affairs. 2007; 26: 111-123.
49. Vijan S, Hwang I, Choi JR, Napierkowski J, Koff J, Inadomi J, Pickhardt P, Wong R. *The cost-effectiveness of virtual colonoscopy in screening for colorectal cancer*. American Journal of Gastroenterology. 2007; 102: 380-90.
50. Schmittdiel J, Vijan S, Fireman B, Elston-Lafata J, Oestericher N, Selby JV. *Using quality-adjusted life-years to measure the clinical benefit and value of diabetes care*. Medical Care. 2007; 45(4): 315-321.
51. Janz NK, Lakhani I, Vijan S, Katz SJ. *Barriers and preferences for colorectal cancer screening*. Preventive Medicine. 2007; 44(5): pending.
52. Cram P, Vijan S, Katz D, Fendrick AM. *Cost-effectiveness of in-home automated external defibrillators for individuals at increased risk of sudden cardiac death*. Journal of General Internal Medicine. 2007; in press.

53. Chan P, Chow T, Kereiakes D, Schloss EJ, Waller T, Eagle K, Hayward RA, Vijan S. *Mortality reduction by prophylactic ICD placement in ischemic cardiomyopathy patients: An effectiveness study*. Archives of Internal Medicine. 2007; in press.
54. Kim C, Herman WH, Vijan S. *Efficacy and cost of postpartum screening strategies for diabetes among women with histories of gestational diabetes*. Diabetes Care 2007; in press.
55. Tunceli K, Bradley CJ, Elston-Lafata J, Pladevall M, Divine G, Goodman A, Vijan S. *Glycemic control and labor market outcomes among people with diabetes*. Diabetes Care 2007; in press.
56. Shekelle P, Vijan S. *Quality indicators for the care of diabetes in vulnerable elders*. Journal of the American Geriatrics Society 2007; in press.
57. Chan P, Nallamothu BK, Gurm HS, Hayward RA, Vijan S. *Cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease*. Circulation 2007; in press.

Manuscripts submitted for publication

58. Vijan S. *Guidelines for Glycemic Control in Type 2 Diabetes*. Submitted to Annals of Internal Medicine.
59. Krein SL, Bernstein SJ, Fletcher CE, Makki F, Goldzweig CL, Watts B, Vijan S, Hayward RA. *Improving eye care for veterans with diabetes: an example of using the QUERI steps to move from evidence to practice*. Revision requested by Implementation Science.
60. Nerenz DR, Joseph C, Williams K, Elston-Lafata J, Moon C, Vijan S. *Population health effects of eliminating racial/ethnic disparities in quality of care*. Submitted to Health Affairs.
61. Volk M, Lok A, Ubel P, Vijan S. *Justice in liver transplantation: incorporating ethical principles into decision analysis*. Submitted to Medical Decision Making.
62. Saini S, Schoenfeld P, Vijan S. *Cost-effectiveness of surveillance colonoscopy in patients with a history of adenomatous polyps*. Submitted to Gastroenterology.
63. Vijan S. *Regression-based multivariable sensitivity analyses of Markov and Monte Carlo models*. Submitted to Medical Decision Making.
64. Vijan S, Hofer TP, Kerr EA, Hayward RA. *Using quality-adjusted life-years to improve quality measurement*. Submitted to Health Affairs.

Non-peer reviewed publications

Is optimal glucose control worthwhile? Patient Care 1998; 32(3): 23-4.

Hayward RA, Vijan S. *Diabetes Care Priorities: Preventing Cardiovascular Complications*. VA Practice Matters, May 2000, Vol. 5, Issue I.

Vijan S. The use of statin therapy in type 2 diabetes. *Diabetes Self-Management*; September/October 2004, p. 65.

Vijan S. Individualizing screening. *VA HSR&D FORUM*. May, 2006.

Vijan S. When should we stop screening? *VA HSR&D FORUM*. May, 2006.

Book chapters/Web-based educational modules/Monographs

1. Vijan S. *Diagnosis and management of type 2 diabetes*. American College of Physician PIER modules. American College of Physicians; published in web form, 2002. Available at <http://pier.acponline.org>
2. Vijan S. The cost-utility of screening for diabetic retinopathy. In: Stichwort: Diabetes. Documentation of an International Symposium. Bonn: mbH & Co, 2002. Pages 37-43.
3. Vijan S. Overview of the Vijan Colorectal Cancer Screening Model. In: Economic Models of Colorectal Cancer Screening in Average-Risk Adults. Eds: Pignone M, Russell L, Wagner J. Washington DC: National Academies Press, 2005. Pages 105-117.
4. NIH Consensus Statement on Celiac Disease. *NIH Consens State Sci Statements*. 2004 June 28-30; 21(1): 1-22.
5. Vijan S. Hypertension in Diabetes. BMJ Clinical Evidence. 2005. Online at <http://www.clinicalevidence.com/ceweb/conditions/dia/0608/0608.jsp>

Abstracts (partial listing)

1. Vijan S, Hofer TP, Hayward RA. *The benefits of glycemic control in type diabetes*.
2. Vijan S, Hwang E, Hofer TP, Hayward RA. *Screening strategies for colon cancer: flexible sigmoidoscopy and fecal occult-blood testing versus colonoscopic screening*
3. Vijan S, Hofer TP, Hayward RA. *Screening intervals for diabetic retinopathy: are current guidelines justifiable?*

4. Ronis, DL, Vijan S, Hayward RA, Phillips CV, Hofer TP. *Diabetes patients' views of treatments.*
5. Stuart N, Vijan S, Ronis D, Hayward RA. *Patient preferences for the care of diabetes.*
6. Wamsteker E-J, Vijan S. *The cost-effectiveness of carotid endarterectomy inpatients with symptomatic 50 to 69% stenoses*
7. Vijan S, Zeber J, Valenstein M. *Should we screen for depression in primary care? A cost-utility analysis.*
8. Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky J, Selker HP. *Effectiveness and cost-effectiveness of t-PA relative to streptokinase in 921 patients treated with thrombolytic therapy: potential clinical and economic benefits of targeting therapy.*
9. Kent DM, Griffith JL, Hayward RA, Vijan S, Beshansky J, Califf RM, Selker HP. *An independently-derived model for selecting patients likely to benefit from tissue plasminogen activator: Validating with GUSTO.*
10. Vijan S, Fitzgerald JT, Stuart N. *Patient attitudes towards diet in type 2 diabetes.* Diabetes 2000;49;A446.
11. Fitzgerald JT, Vijan S, Stuart N. *Insulin therapy and patient attitudes at two VA Centers.* Diabetes 2000;49;A445.
12. Vijan S, Langa K, Stuart N, Hayward RA. *Racial variation in disability in type 2 diabetes.*
13. Vijan S, Langa K, Stuart N, Hayward RA. *Rates, causes, and costs of disability in patients with type 2 diabetes: results from a national sample.*
14. Zeber J, Vijan S, Valenstein M. *Cost-utility of depression screening: usual care versus collaborative treatment.*
15. Krein SL, Klamerus ML, Vijan S, Pawlow A, Reeves P, Hayward RA. *Proactive diabetes case management: expectation versus reality.*
16. Davis JA, Krein SL, Kerr EA, Vijan S, Hayward RA. *Evaluating a VISN-wide multi-faceted intervention to improve diabetes care.*
17. Vijan S, Inadomi J, Fendrick AM, Hofer TP, Hayward RA. *The impact of colorectal cancer screening recommendations on colonoscopy demand.*

Revised 4/1/07